Navigation Links
Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/13/2008

sis and resistance of tumors to

chemotherapies.

-- In 2007, Micromet partnered two of its earlier stage programs. The

company is collaborating with Nycomed on the development of MT203, a

human antibody that neutralizes GM-CSF, a key cytokine involved in

autoimmune diseases and chronic inflammation. In addition, Micromet

has licensed MT293 to TRACON Pharmaceuticals, Inc. MT293 is an

anti-angiogenic antibody that aims to limit tumor growth by preventing

blood vessels to reach the tumor. TRACON initiated a phase 1 clinical

trial in July 2007.

-- In June 2007, Micromet closed a $25 million PIPE transaction, adding to

its shareholder base a number of experienced U.S.-based biotech funds.

Several of Micromet's existing shareholders participated in this

financing round.

Summarizing the events, Christian Itin, Ph.D., President and Chief Executive Officer of Micromet said: "In 2007, we have made significant progress with our BiTE antibodies demonstrating strong clinical activity for MT103 in late-stage non-Hodgkin's lymphoma patients and completing preclinical development of MT110, our first BiTE antibody targeting solid tumors. In 2008, we will broaden the clinical program for MT103 and initiate a first clinical trial for MT110. We will also advance our earlier-stage BiTE antibodies and report on results at clinical and scientific conferences. In addition, we expect to start a phase 2 clinical trial with adecatumumab (MT201) in adjuvant disease in the second half of 2008. Finally, we will continue to explore opportunities for new collaborations in 2008."

Financial Results:

Quarter Ended December 31, 2007

For the three months ended December 31, 2007, Micromet recognized revenues of $7.0 million, compared to $13.8 million for the same period in 2006. Included in 2006 revenues was the receipt of a $10.0 million milestone payment
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
4. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Helix BioPharma reports Q2 2008 highlights, financial results
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
9. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
10. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
11. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Bill Jacobs Automotive, a group of car ... up with the Heartland Blood Center and offering free oil ... drive takes place Saturday, Jan. 18 at the Bill Jacobs ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46637 )  The ...
(Date:1/15/2014)... Westlake Village, Calif. (PRWEB) January 15, 2014 ... cancer treatment and management through the genomic analysis of ... will offer Therapy Finder™, a web-based cancer decision support ... a reporting option with Cynvenio’s ClearID™ genomic test, Therapy ...
(Date:1/15/2014)... A study has been launched to test ... track could help to tackle the problem of obesity.  This ... GP surgery based in Stowmarket) and academics at University Campus ... Telemetry technology, which is inspired by equipment used to collect ...
(Date:1/15/2014)... DTS Language Services, Inc . is pleased ... Life Science organizations who need document translations. Clients will ... their documents in advance with a selection of nearly 50 ... often a critical factor in clinical and scientific fields, and ...
Breaking Biology Technology:Join the Bill Jacobs Auto blood drive and receive a free oil change 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2
... Million to ... Chronic Kidney Disease, EL SEGUNDO, Calif., June 26 DaVita ... chronic kidney,disease and failure (CKD), today announced that its third annual ... Beach, Va. DaVita KAT Walks Across America(TM) are a series of,5k ...
... it, soon you might not, researchers at the University ... have demonstrated an approximate cloaking effect created by concentric ... scientists a step closer to a practical solution for ... theoretical exercise," said Harley Johnson, a Cannon Faculty Scholar ...
... white paper titled “Avanta AC™ Advanced Ceramics ... online. This white paper outlines the challenges ... nanometer scale, as well as the advantages ... ceramic nanopowders are critical to a variety ...
Cached Biology Technology:Third Annual DaVita Kidney Disease Awareness Walks to Hit 20 Cities in 2008 2Silicon photonic crystals key to optical cloaking, researchers say 2 SACHEM Launches New Products for High Purity Advanced Ceramic Powders : Avanta AC™ Advanced Ceramics Solutions Offer Unique Advantages over Inorganic Bases in the Manufacture of Advanced Ceramic Nanoparticles 2
(Date:4/22/2014)... are all sorts of signaling strategies in nature. Peacocks ... satin bowbirds build specialized stick structures, called bowers, and ... bitterling males show off bright nuptial coloration during spawning ... communicate with others. , ... fitness implications for individuals that are either signaling or ...
(Date:4/22/2014)... HOUSTON (April 22, 2014) Biotechnology scientists must ... for new patent and licensing guidelines, according to a ... Policy. , Published in the current issue of the ... on the June 2013 U.S. Supreme Court ruling in ... Genetics that naturally occurring genes are unpatentable. The court ...
(Date:4/22/2014)... orthopedic organizations have presented Beaumont Health System with ... recovery from both athletic and nonathletic injuries. ... awarded a $40,000 grant to fund stem cell-based ... injuries like a ruptured knee anterior cruciate ligament, ... Health, "An anterior cruciate ligament injury is the ...
Breaking Biology News(10 mins):Best practices in communication for the animal world 2Best practices in communication for the animal world 3New patenting guidelines are needed for biotechnology 2New patenting guidelines are needed for biotechnology 3Beaumont awarded grants to study sports-related injury treatment, improve recovery 2
... the puzzles it contains, though, many remain unsolved. We know ... building blocks of each and every cell. But what role ... healthy body, for instance? And what takes place in tumor ... gets out of hand? To get to the bottom ...
... This press release is available in German ... aspect of the human mind. However, how the images and emotions ... heads remains a mystery. Up to now it has not been ... from the Charit hospital in Berlin have now succeeded, for the ...
... With scientific evidence now supporting the age-old wisdom that ... tract infections, people have wondered if there was an ... perhaps in pill form, would be as effective as ... study from researchers at Worcester Polytechnic Institute (WPI) helps ...
Cached Biology News:Cell cultures from a machine 2Scientists measure dream content for the first time 2More power to the cranberry: Study shows juice better than extracts at fighting infections 2
... Hybri-slips are hydrophobic cover slips for ... to genomic arrays on glass slides., ... slips, Hybri-slips do not adsorb probes. ... prior to use. , Avoid RNA ...
These 22x40mm rectangular No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick. • Approx. Pcs Oz : 73...
... in the Microsart e.motion are sterile-sealed, without protective ... specially designed individual package on a band. ... membrane filter units ensures that they are perfectly ... band guarantees uniform dispensing of the individual membrane ...
...
Biology Products: